David Arnold
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 1%
- Long-Term Effects of COVID-19
Papers in
-
- COVID-19 Clinical Research Studies 18
- SARS-CoV-2 and COVID-19 Research 3
-
- Pleural and Pulmonary Diseases 18
- Occupational and environmental lung diseases 8
- Infection Control and Ventilation 5
- Co-authors
- Nick A. Maskell (33 shared papers)Fergus Hamilton (29 shared papers)Anna J. Morley (7 shared papers)Andrew R L Medford (8 shared papers)Duneesha de Fonseka (6 shared papers)Alice Milne (7 shared papers)Karen T Elvers (6 shared papers)Anna Morley (10 shared papers)
- Journals
- European Respiratory Journal (7 papers)The Lancet (6 papers)The Lancet Respiratory Medicine (6 papers)Thorax (6 papers)British Journal of Cancer (3 papers)
- Partner nations
- United KingdomCanadaNew Zealand
In The Last Decade
David Arnold
82 papers receiving 4.5k citations
David Arnold's Hit Papers
Peers
Comparison fields: 5 of 117
- Infectious Diseases 1.8k
- Neurology 1.3k
- Pulmonary and Respiratory Medicine 853
- General Dentistry 8
- Applied Microbiology and Biotechnology 36
Countries citing papers authored by David Arnold
This map shows the geographic impact of David Arnold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Arnold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Arnold more than expected).
Fields of papers citing papers by David Arnold
This network shows the impact of papers produced by David Arnold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Arnold. The network helps show where David Arnold may publish in the future.
Co-authors
The 25 scholars most cited alongside David Arnold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study Hit paper breakdown → | 2021 | 504 |
| 2 | Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort Hit paper breakdown → | 2020 | 485 |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 5 | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Hit paper breakdown → | 2022 | 310 |
| 6 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 7 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 8 | 2021 | 213 | |
| 9 | 2018 | 145 | |
| 10 | Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study Hit paper breakdown → | 2023 | 95 |
| 11 | 2022 | 87 | |
| 12 | 2016 | 84 | |
| 13 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 14 | 2013 | 65 | |
| 15 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 16 | 2021 | 63 | |
| 17 | 2017 | 60 | |
| 18 | 2021 | 55 | |
| 19 | 2017 | 50 | |
| 20 | 2020 | 50 |
About David Arnold
David Arnold is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine, Neurology, Epidemiology and Hematology, having authored 87 papers that have together received 4.7k indexed citations. Recurring topics across this work include Pleural and Pulmonary Diseases (18 papers), COVID-19 Clinical Research Studies (18 papers), Long-Term Effects of COVID-19 (15 papers), Occupational and environmental lung diseases (8 papers), Infection Control and Ventilation (5 papers), Pneumonia and Respiratory Infections (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). The work is most often cited by research in Infectious Diseases (1.8k citations), Neurology (1.3k citations), Pulmonary and Respiratory Medicine (853 citations), General Dentistry (8 citations) and Applied Microbiology and Biotechnology (36 citations). David Arnold has collaborated with scholars based in United Kingdom, Canada and New Zealand. Frequent co-authors include Nick A. Maskell, Fergus Hamilton, Anna J. Morley, Andrew R L Medford, Duneesha de Fonseka, Alice Milne, Karen T Elvers, Anna Morley, James William Dodd and Marie Attwood. Their work appears in journals such as European Respiratory Journal, The Lancet, The Lancet Respiratory Medicine, Thorax and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.